The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

[1]  P. V. van Diest,et al.  Active HIF-1 in the Normal Human Retina , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  H. Armah.  Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas , 2010 .

[3]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[4]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Tominaga,et al.  Analysis of IDH1 and IDH2 mutations in Japanese glioma patients , 2009, Cancer science.

[6]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[7]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[8]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[10]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[11]  D. Louis,et al.  Faculty Opinions recommendation of Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. , 2009 .

[12]  P. Ratcliffe,et al.  Puzzling Patterns of Predisposition , 2009, Science.

[13]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[14]  P. Kleihues,et al.  Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome , 2009, Acta Neuropathologica.

[15]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[16]  C. Thompson,et al.  Metabolic enzymes as oncogenes or tumor suppressors. , 2009, The New England journal of medicine.

[17]  A. Marchetti,et al.  IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.

[18]  Su-Min Lee,et al.  Silencing of cytosolic NADP+-dependent isocitrate dehydrogenase by small interfering RNA enhances the sensitivity of HeLa cells toward staurosporine , 2009, Free radical research.

[19]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[20]  C. Van Noorden,et al.  Metabolic mapping by enzyme histochemistry in living animals, tissues and cells. , 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[21]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[22]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[23]  G. Bánhegyi,et al.  Isocitrate dehydrogenase: A NADPH-generating enzyme in the lumen of the endoplasmic reticulum. , 2008, Archives of biochemistry and biophysics.

[24]  W. Ying.  NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. , 2008, Antioxidants & redox signaling.

[25]  M. Aghili,et al.  Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review , 2008, Journal of Neuro-Oncology.

[26]  T. Ozben.  Oxidative stress and apoptosis: impact on cancer therapy. , 2007, Journal of pharmaceutical sciences.

[27]  Sieger Leenstra,et al.  Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. , 2007, Cancer research.

[28]  Jeen-Woo Park,et al.  Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase , 2007, Molecular and Cellular Biochemistry.

[29]  Richard A. Miller,et al.  The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy , 2005, Cancer biology & therapy.

[30]  C. J. Noorden,et al.  Reaction rate studies of glucose-6-phosphate dehydrogenase activity in sections of rat liver using four tetrazolium salts , 1985, The Histochemical Journal.

[31]  Jianping Ding,et al.  Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity* , 2004, Journal of Biological Chemistry.

[32]  Pasquale Chieco,et al.  A user's guide for avoiding errors in absorbance image cytometry: a review with original experimental observations , 2004, The Histochemical Journal.

[33]  C. Van Noorden,et al.  Reduced nicotinamide adenine dinucleotide phosphate and the higher incidence of pollution‐induced liver cancer in female flounder , 2003, Environmental toxicology and chemistry.

[34]  B. Geisbrecht,et al.  The Human PICD Gene Encodes a Cytoplasmic and Peroxisomal NADP+-dependent Isocitrate Dehydrogenase* , 1999, The Journal of Biological Chemistry.

[35]  C. J. Noorden,et al.  Enzyme Histochemistry: A Laboratory Manual of Current Methods , 1993 .

[36]  D. Koshland,et al.  Sensitivity of metabolic fluxes to covalent control. , 1985, Current topics in cellular regulation.

[37]  A. Seligman.  [123] Histochemical methods for dehydrogenases , 1963 .